Yesterday saw the news that Tokai Pharmaceuticals ($TKAI) have filed plans for a $75M IPO, largely based on the potential of their phase 2 prostate cancer compound, galeterone.
Cellectis is a Paris based biotechnology company, (NYSE alternext: ALCLS.PA) with an aspiring “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
At ASCO 2014, one of the posters that attracted a lot of attention was the one from Kite Pharma ($KITE) on their rapid cell expansion (RACE) technology for the production of engineered autologous T cell therapy.
The melanoma oral abstracts session at ASCO 2014 was packed as a full house in the Arie Crown lecture theatre listened to the latest on new immuno-oncology therapies that are leading a revolution in melanoma treatment.
In her ASCO Gastrointestinal Cancer symposium (ASCO GI) keynote presentation earlier this year, Elizabeth M. Jaffee MD described the future of immunotherapy as being in combinations.
A predictive biomarker for prostate cancer drug resistance may lead to new drug development opportunities.
Post ASCO 2014, many journalists and commentators have hotly declared the third-generation EGFR inhibitor CO-1686 from Clovis Oncology to be a “loser.”
Chicago – it’s the last day of the American Society of Clinical Oncology (ASCO) annual meeting. There’s been a record attendance this year with over 30,000 people coming to Chicago to hear the latest news and research on cancer treatments.
Chicago – it’s day 4 of the ASCO (American Society of Clinical Oncology) annual meeting. Sunday at ASCO can be a bit hit or miss depending on whether the plenary selection committee makes a good choice in which studies to give the “glory” and how interesting they are. It’s certainly been a busy meeting, although I have to say going round the poster halls has been a horrible experience. For the first time this year, they doubled up the trials in progress posters, which makes it like a rugby scrum to reach the QR code to get a copy, and all it means is that people use smaller text to cram the same material into a smaller area. People do want to talk people about what’s going on, the rational for trials and it must be a miserable experience for presenters to be faced with such cramped conditions. Memo to ASCO – it was not a good idea and the new poster numbering layout is really hard to follow. It’s not as if there is a shortage of space.
The ASCO 2014 conference here in Chicago is in full swing as it enters day 3. We’re continuing our coverage of the meeting with our daily live blog where we post regular updates of data that catches our interest or quick notes from sessions we’ve been to.